MILAN, Italy, July 31, 2026 – Italfarmaco S.p.A. today announced a managed entry agreement with the Georgian Ministry of Health for givinostat (Duvyzat®) as a treatment for patients with Duchenne muscular dystrophy (DMD). Based on the European Commission (EC) approval in June 2025, givinostat will be available in Georgia under this agreement for patients aged six years and over who are ambulant at the start of treatment, when taken together with corticosteroids.